Hutchmed Licenses Ex-Greater China Rights of HMPL-A830 to GSK for $1.295 Billion
Start here
Hutchmed has granted GSK global development and commercialization rights to HMPL-A830, excluding mainland China, Hong Kong, Macau and Taiwan, in a deal worth up to $1.295 billion. HMPL-A830 is the third molecule to emerge from Hutchmed's in-house antibody-targeted conjugate (ATTC) platform. The asset entered its global Phase Ia trial in September 2026, with sites opened in both China and the United States. The transaction strengthens Hutchmed's licensing track record while giving GSK a clinical-stage ATTC candidate for development outside Greater China. Open questions include the Phase Ia trial's safety and efficacy readout, the specific tumor types to be pursued, and the pace at which GSK advances the program into later-stage development.
Written by a model from the reports · updated 4 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- WeChatHutchmed Licenses Ex-Greater China Rights of HMPL-A830 to GSK in $1.295 Billion Deal
Hutchomed has licensed global development and commercialization rights to HMPL-A830, excluding mainland China, Hong Kong, Macau and Taiwan, to GSK, in a deal totaling $1.295 billion. HMPL-A830 is the third molecule from Hutchmed's in-house ATTC (antibody-targeted conjugate) platform, and its global Phase Ia trial began in September 2026 in both China and the United States.
Coverage and heat for this story
Reports so far 1·Heat now 7·Peak heat 10 (Oct 21 13:00)·Reports, 24h +1
Two panels, same clock (pointer stays in sync): top is cumulative editorial reports — only rises; last point = All reports; slope = new reports that hour. Bottom is Live-board heatIndex — 7-day participants with a 24-hour half-life, so it can fall when talk cools.